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Objective: Anesthetic preconditioning may contribute to the cardioprotective effects of sevoflurane in patients
having coronary artery bypass surgery. We investigated whether 2 different sevoflurane administration protocols
can induce preconditioning in patients having coronary artery bypass.
Methods: Thirty patients were randomly allocated to 1 of 3 groups. All patients received a total intravenous an-
esthesia with sufentanil (0.3 mg1 $ kg$ h1) and propofol as target controlled infusion (2.5 mg/mL). The control
group had no further intervention; 10 minutes prior to establishing the extracorporeal circulation, patients of the
sevoflurane-I group received 1 minimum alveolar concentration of sevoflurane for 5 minutes. Patients of the sev-
oflurane-II group received (2 times) 5 minutes of sevoflurane, interspersed by 5-minute washout 10 minutes prior
to extracorporeal circulation. Troponin I was measured as marker of cardiac cellular damage.
Results: Peak levels of troponin I release were observed at 4 hours after cardiopulmonary bypass and were not
affected by 1 cycle of sevoflurane administration (controls: 14 3 ng/mL vs sevoflurane-I group, 14 3 ng/mL).
Two periods of sevoflurane preconditioning significantly reduced cellular damage compared with controls (peak
troponin I level sevoflurane-II group, 7  2 ng/mL).
Conclusion: These data show that sevoflurane-induced preconditioning is reproducible in patients having coro-
nary artery bypass but depends on the preconditioning protocol used.Supplemental material is available online.
Volatile anesthetics induce pharmacologic preconditioning
of the heart (APC). Volatile anesthetics can also provide car-
dioprotective effects in the ischemia-reperfusion situation of
cardiac surgery.1-3 To which extent the phenomenon of APC
might contribute to the clinical cardioprotection is still a mat-
ter of debate. In contrast to the large number of experimental
studies investigating APC, mostly focusing on its signal
transduction,4 only a few clinical studies are available inves-
tigating the effects of APC in humans.5
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doi:10.1016/j.jtcvs.2008.04.0341436 The Journal of Thoracic and Cardiovascular SuThe first indirect advice was provided by Belhomme and
colleagues in 19996; they demonstrated that isoflurane (2.5
Vol%) administered before aortic crossclamping in coronary
artery bypass graft (CABG) surgery increased the 50 nucleo-
tidase activity in right atrial tissue,6 a marker of protein kinase
C (PKC) activation, which is a central step in APC in exper-
imental studies.7 However, a decrease in myocardial injury as
measured by troponin I (TnI) or creatine kinase (CK)-MB
release was not observed.6 A more recent study investigated
if sevoflurane (4 Vol%) can induce preconditioning in
CABG patients.8 There was no washout of the volatile anes-
thetic before ischemia in this study (which is by definition
a prerequisite for the preconditioning phenomenon). Again,
no differences regarding myocardial injury as measured by
CK-MB and troponin-T release were observed. These results
suggest that APC might be present in humans, but the effect is
still inconsistent. A significant inhomogeneity in the experi-
mental setup is evident in clinical APC studies, using differ-
ent time periods of APC,9 different concentrations of volatile
anesthetics,8 and inclusion of a washout period6 or not.8
In animal studies, myocardial protection by ischemic
preconditioning (IPC) is strengthened by multiple cycles of
short ischemia and reperfusion.10 In multiple cycles of IPC,
it is necessary to inhibit different parallel pathways to block
cardioprotection (eg, PKC as well as protein tyrosine kinase),
whereas in single-cycle IPC, the cardioprotection is com-
pletely abolished by blocking only 1 of these 2 kinases.10
Multiple cycles of sevoflurane preconditioning in a rat model
in vivo strengthened the cardioprotective effect of APC.11rgery c June 2009
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APC ¼ anesthetic-induced pharmacologic
preconditioning of the heart
BNP ¼ brain natriuretic peptide
CABG ¼ coronary artery bypass graft
CI ¼ cardiac index
CK ¼ creatine kinase
CPB ¼ cardiopulmonary bypass
CVP ¼ central venous pressure
dP/dtmax ¼ maximum rate of LV
pressure increase
EuroSCORE ¼ European System for Cardiac
Operative Risk Evaluation
ICU ¼ intensive care unit
IPC ¼ ischemic preconditioning
LV ¼ left ventricular
MAC ¼ minimum alveolar concentration
MAP ¼ mean arterial pressure
PKC ¼ protein kinase C
TnI ¼ troponin I
We hypothesized that the concept of APC is applicable in the
setting of CABG procedures in humans but might depend on
the preconditioning protocol. We looked for myocardial in-
jury (cardiac TnI release) and myocardial function as mea-
sured by intraventricular tip manometer after application
of 1 or 2 cycles of sevoflurane preconditioning in patients
having CABG surgery.
METHODS
The study was performed according to the Declaration of Helsinki prin-
ciples. The Ethical Committee of the Heinrich-Heine-University Du¨ssel-
dorf, Germany approved the study, and written informed consent was
obtained from each patient. Patients having isolated coronary revasculariza-
tion were included. Exclusion criteria were physical American Society of
Anesthesiology status 4 or 5, angina during the previous 72 hours, unstable
angina, acute myocardial infarction, ejection fraction lower than 40%, con-
gestive heart failure, emergency procedures, former CABG surgery, concur-
rent valve repair, oral antidiabetics, or theophylline therapy. Cardiac
operative risk was calculated using the European System for Cardiac Oper-
ative Risk Evaluation (EuroSCORE).12
Patients were randomly (by using sealed envelopes) allocated to the con-
trol (no further specific treatment), SEVO-I or SEVO-II group. Ten minutes
prior to establishing cardiopulmonary bypass (CPB), patients of the SEVO-I
group received 1 minimum alveolar concentration (MAC) of sevoflurane (2
Vol%) for 5 minutes. Patients of the SEVO-II group received 2 cycles of 1
MAC sevoflurane for 5 minutes, interspersed by 5-minute washout, 10 min-
utes prior to establishing CPB (see Figure 1).
Anesthesia, Surgery, and Study Protocol
The detailed information is available as an online supplement (Appendix
E1).
Acetylsalicylic acid therapy was discontinued 1 week prior to surgery; all
other preoperative medications were continued until the morning of the op-
eration. Patient monitoring included continuous 5-lead electrocadiographicThe Journal of Thoracic and Cregistration with ST-segment analysis (leads II and V5), pulse oximetry, in-
vasive radial artery blood pressure measurement, central venous pressure
(CVP), pulmonary artery catheters with continuous mixed venous saturation
and cardiac output measurement (CCOmbo, Edwards Lifescience, Irvine,
CA), capnography, rectal temperature, and urine output.
Anesthesia was induced and maintained with propofol target-controlled
infusion with a plasma target concentration of 2.5 mg/mL plasma, sufentanil
(0.3 mg $ kg1 $ h1) and pancuronim bromide (0.1 mg/kg).
Myocardial revascularization was performed according to the standard
procedure of the University of Du¨sseldorf by a single surgeon (A.B.) with
warm (34C) blood cardioplegia.
According to the study protocol, norepinephrine was used to keep mean ar-
terial pressure (MAP) above 70 mm Hg, and dobutamine was used to maintain
cardiac index (CI) above 2.5 L $min1 $m2. An overview of the time points of
hemodynamic measurements and blood sampling is given in Figure 1.
Patients, surgeon, and perfusionists were blinded regarding the enroll-
ment into the study groups. After surgery, patients were transferred to the
intensive care unit (ICU) and received routine therapy, including fast wean-
ing from the ventilator. All decisions regarding medical care on the ICU and
the ward after the operation were done by physicians and nurses blinded to
the study protocol.
Hemodynamic Data Analysis
Global hemodynamic variables (MAP, CVP, pulmonary artery pressure,
pulmonary artery occlusion pressure, CI, and heart rate) were measured at
regular time points (see Figure 1). Additionally, we assessed left ventricular
(LV) performance in terms of systolic (LV peak systolic pressure and max-
imum rate of LV pressure increase [dP/dtmax]) and diastolic function (time
constant of LV isovolumetric relaxation). dP/dt was direct calculated by the
computer system (PowerLab, ADInstruments, Spechbach, Germany). End-
diastolic pressure was timed at the beginning of the sharp upslope of the LV
dP/dt tracing. Mixed venous saturation and CI were measured continuously
and recorded at regular intervals.
Biochemical Analysis
In all patients, blood samples were taken at time points T1 (baseline), T7
(10 minutes post-CPB), T12 (4 hours post-CPB), T14 (12 hours post-CPB),
T15 (24 hours post-CPB), T16 (48 hours post-CPB), and T17 (72 hours
post-CPB, see Figure 1). We measured cardiac TnI, CK and its myocardial
specific isoform CK-MB, and brain natriuretic peptide (BNP) as markers of
cellular injury and myocardial dysfunction, respectively. Blood samples
were centrifuged and plasma was stored at80C until measurement. TnI
(microparticle enzyme immunoassay, Abbott, Wiesbaden, Germany), CK,
and CK-MB analyses were performed in our routine laboratory, and mea-
surement of BNP levels were done by Siemens Medical Solutions Diagnos-
tics (Fernwald, Germany). Institutional threshold values for TnI are 0.4
ng/mL as reference value, 0.5 to 2.0 ng/mL for suspicious myocardial ische-
mia, and 2.0 ng/mL for suspicious myocardial infarction.
Tissue Fractionation and Western Blot Analysis
Tissue fractionation and subsequent Western blot assay off shock-frozen
right atrial tissue was performed as previously described.13 Cytosolic (P1),
membrane (P2), and the particulate fraction (P3) were electroblotted using
the respective first antibody for the phosphorylated and total PKC isoforms
a (PKCa) and e (PKCe) and the phosphorylated Src kinase (tyrosine 416). For
detection of total PKCe, we used anti-PKCe antibody (1:10000; Upstate,
Lake Placid, NY); for phospho-PKCe, anti-phospho-PKCe (ser 729)
(1:10000, Upstate); for total PKCa, anti-PKCa (1:10000, Upstate); for phos-
pho-PKCa, anti-phospho-PKCa (1:10000, Upstate); and for phospho-Src,
the corresponding antibody (1:10000, Cell Signalling, Danvers, MA). As
internal standard we used antibodies against a-tubulin (1:50000, Sigma,
Taufkirchen, Germany) in total PKCa and PKCe analysis, or actin (1:10000,
Sigma, Taufkirchen, Germany) in phospho-Src blots, respectively.ardiovascular Surgery c Volume 137, Number 6 1437
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DFIGURE 1. Experimental protocol; T0 to T17 time points of measurements (hemodynamic and/or laboratory samples). AOX, Aortic crossclamping (¼myo-
cardial ischemia); CPB, cardiopulmonary bypass; TCI, target-controlled infusion of propofol; MAC, minimum alveolar concentration; OP, operative; ICU,
intensive care unit. Sevo I group received 1 minimum alveolar concentration of sevoflurane for 5 minutes before cardiopulmonary bypass; Sevo II group re-
ceived (2 times) 5 minutes of sevoflurane, interspersed by 5-minute washout 10 minutes prior to extracorporeal circulation.Statistical Analysis
Primary end point of the study was reduction of myocardial damage in
terms of TnI release. Sample size calculation was based on the assumption
that the SD of the means of the TnI plasma levels will be 4.5 ng/mL, a ¼
0.05, and b¼ 0.8. A sample size of 10 patients in each group was necessary
to detect a difference of the means of 40% (GraphPad StatMate, San Diego,
CA).
All data were tested for normal distribution (GraphPad Prism 4 for Win-
dows, Graph Pad). Categorical data were analyzed by using Fisher exact
test. Parametric data were analyzed by using a 2-way analysis of variance
followed by Dunnett test as post hoc test with reference to the control group
for group effects and to baseline measurements for time effects. Data are
presented as mean  standard deviation or median and range.
RESULTS
There were no significant differences regarding preopera-
tive demographic data and predicted additive risk deter-
mined by EuroSCORE, which showed a medium risk in
all groups (Table 1). The number of bypass grafts and dura-
tion of aortic crossclamping were similar in all 3 groups
(Table 1). Lengths of postoperative intubation, postopera-
tive stay in the ICU, as well as length of hospital stay
were not different between controls and interventional
groups (Table 1).
Global hemodynamics were not different during baseline
or at the end of the observation period (24 hours post-CPB;
T15; Table E1). Before starting CPB, we observed a reduced1438 The Journal of Thoracic and Cardiovascular Suheart rate and an increased pulmonary artery wedge pressure
in the SEVO-II group compared with control group. At T13,
an increased CI in SEVO-II group compared with the control
group was seen, but this effect was abrogated at T15. In both
SEVO groups, CI was increased compared with baseline
values. dP/dtmax was increased in the SEVO-II group 10
minutes after CPB, as well as the LV pressures (see Table 2).
Heart rate was increased in all patients after CPB due to ex-
ternal cardiac pacing.
TnI plasma concentrations were reduced in SEVO-II pa-
tients compared with SEVO-I patients and control group
(see Figure 2). Regarding CK, CK-MB, and BNP, no signif-
icant differences between the groups were detected (Table
E2).
Although no change in phosphorylation of PKCe after
APC was determined (ratio phospho PKCe/total PKCe: con-
trol group, before APC 0.34  0.1, after APC 0.34  0.14;
SEVO-I group, 0.33  0.1 vs 0.34  0.1; SEVO-II group,
0.3  0.1 vs 0.31  0.1), translocation of PKCe to the par-
ticular fraction of the right atrial tissue was observed in the
SEVO-II group (ratio total PKCe after APC to before
APC: P1 1.1  0.2; P2 1.0  0.1; P3 2.5  1.4; P< .001
vs P1 and P2), but not in the SEVO-I group (P1 1.1  0.3;
P2 1.2  0.4; P3 1.6  0.7) or in the control group (P1
1.1  0.4; P2 1.0  0.3; P3 1.1  0.3).rgery c June 2009
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fore APC 0.6 0.14, after APC 0.64 0.15; SEVO-I group
0.59  0.1 vs 0.59  0.12 and SEVO-II group 0.56  0.11
vs 0.61  0.21; ratio total PKCa before vs after APC: con-
trol group, P1 1.0  0.2, P2 0.96  0.1, P3 0.94  0.2;
SEVO-I group, P1 0.98  0.1, P2 0.98  0.2, P3 0.91 
0.3; SEVO-II group, P1 1.06  0.1, P2 1  0.1, P3 0.97
 0.1) nor tyrosine kinase Src (ratio phospho-Src before
vs after APC, control group 0.95  0.3, SEVO-I group
0.91  0.2, SEVO-II group 0.86  0.3) was activated by
sevoflurane administration.
DISCUSSION
Previous studies indicated that volatile anesthetics have
direct cardioprotective properties, independent of hemody-
namic or metabolic changes.14 In experimental in vitro and
in vivo models, volatile anesthetics have been shown to pre-
condition the heart, thereby protecting the myocardium
against infarction and postischemic dysfunction.4,7,15 We
demonstrated in the present study that APC can be achieved
TABLE 1. Patient characteristics
Control
(n ¼ 10)
SEVO-I
(n ¼ 10)
SEVO-II
(n ¼ 10)
Preoperative data
Sex (M/F) 9/1 9/1 9/1
Age (y) 66  8 65  9 67  8
BMI (kg/m2) 30  4 26  4 29  3
EuroSCORE, median/range 4 (3–8) 4 (0–7) 5 (0–6)
Preoperative medication
ACE inhibitor 7 7 8
ASS 0 0 0
Bronchodilating agents 1 1 1
Ca2þ antagonists 1 1 2
Diuretics 4 3 5
Heparin 7 6 7
Insulin 0 0 0
Molsidomine 1 5 2
Nitrates 3 3 2
ß-blocker 8 8 7
Statin 6 6 7
Theophylline 0 0 0
Intraoperative data
No. of bypass (median/range) 4 (2–4) 3 (2–4) 4 (2–5)
CPB time (min) 98  29 95  26 95  23
Aortic crossclamp time (min) 52  18 52  12 51  18
Reperfusion time (min) 39  14 37  13 41  9
Postoperative data
Length of intubation (min) 348  191 306  166 296  166
Length of stay ICU (h) 25  8 22  4 21  1
Length of stay hospital (d) 15  5 13  6 12  5
BMI, Body mass index; EuroSCORE, European System for Cardiac Operative Risk
Evaluation; ACE, angiotensin-converting enzyme; ASS, acetylsalicylic acid (ASS
was withdrawn in all patients); Ca2þ antagonist, calcium channel antagonists; CPB,
cardiopulmonary bypass; ICU, intensive care unit.The Journal of Thoracic and Cain humans by 1 MAC sevoflurane; however, the cardiopro-
tection depends on the preconditioning protocol. Reduction
of cellular damage goes along with improvement of myocar-
dial function early after termination of extracorporeal circu-
lation.
Several studies have addressed the potential clinical im-
plication of cardioprotection by volatile anesthetics in coro-
nary artery surgery patients, looking on cellular enzyme
release and myocardial function.1,2,8,16 Although some stud-
ies show beneficial effects of volatile anesthetics, others do
not, leaving the concept of APC in humans questionable.
This is in strong contrast to animal studies and might be
caused by the different methods of the clinical investiga-
tions. Preconditioning includes a short stimulus (ischemic
or pharmacologic stimulus), followed by definition by a short
reperfusion or washout period of the pharmacologic stimu-
lus, respectively.17 Therefore, to fulfill the criteria of precon-
ditioning, the volatile anesthetic must not be present at the
onset of sustained myocardial ischemia. There are only
a few clinical studies that meet this criteria. Belhomme
and colleagues6 used high-dose isoflurane (2.5 Vol%) for
15 minutes followed by a 10-minute washout period before
aortic crossclamping. They demonstrated an increase in 50
nucleotidase activity (a marker of PKC activity) in right
atrial tissue but could not show significant reduction of
TnI or CK-MB release. Tomai and associates18 used a stim-
ulus of 15 minutes of isoflurane followed by 10-minute
washout before CPB.18 They could not detect differences re-
garding myocardial function and cellular enzyme release be-
tween the control and the study group (20 patients in each
group). Similar results were obtained from a second study
of this group in diabetic patients.19 Piriou and colleagues20
investigated 72 patients in a 2-center, randomized study.
APC was induced with sevoflurane for 15 minutes (1 MAC)
followed by 15-minute washout prior to CPB and myocar-
dial ischemia. They did not observe a reduction in TnI. There
was no difference in the activity of PKC, tyrosinkinase, or
mitogen-activated protein kinase p38. But in the APC group,
they observed fewer patients with low cardiac output. De
Hert and associates9 investigated if the timing of the sevo-
flurane administration is crucial for the sevoflurane-induced
cardioprotection. They administered sevoflurane after ster-
notomy until the start of CPB at a dose between 0.5 and
2.0 Vol% (preconditioning group), from the begin of reper-
fusion until the end of the procedure (postconditioning
group), or throughout the entire procedure (sevoflurane for
all); patients of the control group were anesthetized with pro-
pofol. In the preconditioning and the postconditioning
group, the authors observed a trend to lower TnI plasma
levels after the CABG procedure in their patients, but a sig-
nificant reduction of this biomarker for myocardial damage
was determined only in the sevoflurane for all group.9 As
it is known from experimental data, where multiple precon-
ditioning cycles exert stronger cardioprotective effectsrdiovascular Surgery c Volume 137, Number 6 1439
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Baseline (T1) SEVO-I (T2) WASH-I (T3) SEVO-II (T4) WASH-II (T5) 3 min post-CPB (T6) 10 min post-CPB (T7)
LVPMAX (mm Hg)
CON 91  20 90  31 100  13 99  19
SEVO-I 106  11 85  13y 101  11 97  14 103  16
SEVO-II 106  8 94  13 105  16 94  14 101  8 121  13* 120  21
LVPED (mm Hg)
CON 12.6  3 12.6  3 16.2  4 15.0  3
SEVO-I 13.0  3 11.8  3 12.7  3 19.0  9y 15.6  3
SEVO-II 17.0  3* 15.4  2 17.3  4 16.5  4 15.0  4 21.4  5* 19.7  5*
dP/dtmax (mm Hg/s)
CON 872  211 830  200 1130  555 916  208
SEVO-I 1042  325 938  280 1055  330 1173  475 1441  508
SEVO-II 1015  165 874  190 1058  238 892  206 1016  179 1447  363y 1735  584*y
t (ms)
CON 54  15 57  17 46  20 53  33
SEVO-I 58  15 67  11 61  20 58  30 48  16
SEVO-II 57  15 64  20 58  13 62  20 52  10 44  12 45  17
LVPMAX,Maximal left ventricular pressure; LVPED, end-diastolic left ventricular pressure; dP/dtmax,maximal rate of pressure change of the left ventricular pressure; t, time constant
of decrease in left ventricular isovolumic pressure; CPB, cardiopulmonary bypass; CON, control group. For explanation of the time points and groups, see Figure 1; data are mean
standard deviation. *P< .05 versus control group; yP< .05 versus baseline.compared with single-cycle preconditioning protocols,10 we
investigated whether multiple cycles are able to induce APC
in humans having CABG procedures. Our data now show
for the first time that reduction of cellular damage accompa-
nied by improvement of early recovery of myocardial func-
tion depends on the preconditioning protocol: although one
cycle of sevoflurane administration was not protective, 2 cy-
cles reduced the cellular damage.
Other clinical studies either used no preischemic washout
or applied the volatile anesthetic before and after CPB or
during the whole surgical procedure. Accordingly, these
studies might also have included cardioprotective effects
other than preconditioning (ie, effects during ischemia or
during reperfusion [postconditioning]). Julier and col-
leagues8 applied a high dose of sevoflurane (4 Vol%) while
the patient was already connected to the CPB and did not
include a washout period. They found no differences in
TnI release between groups, but they observed a decrease
of pro N terminal (NT) brain natriuretic peptide (BNP)
(pro-NT-BNP), a marker of myocardial dysfunction, after
sevoflurane pretreatment and a translocation of PKC-d to
the sarcolemma and of PKC-e to mitochondria, intercalated
discs, and the cell nucleus in right atrial tissue. Due to the
high sevoflurane concentration, they had to administer phen-
ylephrine to maintain perfusion pressure. Phenylephrine in-
fusion as well as CPB might also induce a preconditioning
effect,21 thereby probably masking protective effects of sev-
oflurane administration. In contrast to this study, we demon-
strated a reduction of TnI after 2 cycles of sevoflurane
preconditioning, but there was no reduction of BNP (see
Figure 2 and Table E2). We observed a translocation of
PKC-e from the cytosolic fraction to the particulate fraction1440 The Journal of Thoracic and Cardiovascular Sthat contains the nuclei of the right atrial cells. These differ-
ences might be explained by the different protocols used. In
addition, Julier and colleagues8 used aprotinin in their pa-
tients, and we did not. Aprotinin is a protease inhibitor
that in animal experiments can abolish 1-, 2-, and 3-cycle
FIGURE 2. Plasma concentrations of troponin I during the observation
period of the study. The horizontal line marks the level of positive values
for troponin I representing myocardial infarction. SEVO-I group received
1 minimum alveolar concentration of sevoflurane for 5 minutes before
CPB; SEVO-II group received (2 times) 5 minutes of sevoflurane, inter-
spersed by 5-minute washout 10 minutes prior to extracorporeal circulation
and CPB. Control patients were not treated with sevoflurane. Data are mean
 standard deviation. yyyP< .001 versus baseline (control and SEVO-I
group), yP< .05 versus baseline (SEVO-II group); *P< .05, ***P<
.001 control and SEVO-I group versus SEVO-II group at corresponding
time points. CPB, Cardiopulmary bypass.urgery c June 2009
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oprotective effects of volatile anesthetics in previous clinical
studies.8,9
Besides aprotinin, which is a very strong blocker of pre-
conditioning and was avoided in the present study, patients
might face a variety of other factors that partially can block
preconditioning in animal experiments, like elevated glu-
cose levels,22 intake of oral antidiabetics,23 or beta-adreno-
ceptor blockers.24 In our study, most patients were on
beta-blocker and mean glucose increased to 145 mg/dL dur-
ing CPB. One might speculate that a partial blockade of the
preconditioning mechanism by these factors could explain
the presence of only 1 activation way of PKC (ie, only trans-
location of the enzyme) and the need for a stronger stimulus
to induce organ protection. In IPC, multiple cycles of pre-
conditioning ischemia are more protective than a single cy-
cle,10 and our data support that this concept of a stronger
stimulus to protect the heart is also observed in APC. Other
perioperative factors that might influence the ischemia-re-
perfusion injury were similar in our patients. All patients
were completely revascularized, each anastomosis was per-
formed during 1 cycle of blood cardioplegia according to the
technique of Calafiori, all operations were performed by the
same surgeon, and no intermittent reperfusion was used. As
different levels of anesthesia during the preconditioning pro-
tocol might lead to a better oxygen demand–supply ratio, we
stopped for the preconditioning procedure (ie, sevoflurane
administration) the propofol application and maintained in
our patients the same depth of anesthesia in terms of bispec-
tral index (BIS) levels (at T2, control group: 32 7, SEVO-I
group: 31  8, SEVO-II group: 30  10; T4, control group:
32 6, SEVO-I group: 32 5, SEVO-II group: 34 8). To
estimate the additive patient risk, we calculated the Euro-
SCORE for each patient with an equal distribution of Euro-
SCOREs within the groups (Table 1). As no differences in
perioperative factors are obvious, we conclude that the ob-
served effect is most likely due to the administration of sev-
oflurane.
We did not measure plasma or myocardial levels of sevo-
flurane but measured routine end-tidal sevoflurane concentra-
tion in our patient. Using a high fresh gas flow during the
preconditioning period, we were able to achieve fast washin
and washout of the volatile anesthetic (in every patient we
achieved a measured level of 0% in the end-tidal respiratory
gas, measured at 5 minutes after sevoflurane administration).
Other clinical studies investigating volatile anesthetic-in-
duced cardioprotection in CABG patients applied the sub-
stances either before or after ischemia or during the whole
surgical procedure, probably combining different cardiopro-
tective effects like pre- and postconditioning. There is evi-
dence that the most uniform cardioprotective effect can be
achieved when the volatile anesthetic (eg, sevoflurane) is ad-
ministered throughout the surgical procedure.9 Multicenter,
randomized clinical trials demonstrated cardioprotective ef-The Journal of Thoracic and Cfects of desflurane in CABG surgery with CPB2 as well as in
patients subjected to off-pump coronary artery grafting.1 In
contrast, a single-center study including 18 patients failed to
show beneficial effects of sevoflurane-based anesthesia
compared with propofol-based anesthesia at comparable bis-
pectral levels.25 De Hert and colleagues9,26 showed in differ-
ent studies that inhalational anesthetics are beneficial
compared with intravenous anesthetics in CABG surgery pa-
tients. However, administration of sevoflurane only before
or after myocardial ischemia was less effective compared
with administration of the volatile anesthetic throughout
the procedure9; the later resulted in reduced length of stay
on the ICU and in the hospital.
One might ask what will happen if we give 10 minutes of
sevoflurane instead of 2 times 5 minutes prior to CPB. This
question cannot be answered by our study. We have decided
to increase the number of stimuli, because from animal stud-
ies it is well known that multiple cycles of IPC enhance the
cardioprotection from ischemic- and anesthetic-induced pre-
conditioning. Additionally, other groups tried with higher
concentration8 or longer administration9 to precondition the
myocardium but failed to show clear cardioprotective effects.
We used cardiac TnI as biomarker for myocardial dam-
age, which has high myocardial tissue specificity and high
sensitivity, reflecting even very small amounts of myocar-
dial necrosis27 and irreversible cell injury in surgical pa-
tients.28 Cardiac TnI might predict short- and long-term
outcome after CABG surgery.29 However, our study was
not designed and powered to measure short- or long-term
outcome after CABG surgery, allowing no conclusion on
patient outcome after myocardial preconditioning with vol-
atile anesthetics. In contrast to a previous study,8 we did not
observe significant differences in BNP levels between the
groups. This discrepancy might be caused by different meth-
odologies used in both studies as discussed earlier.
Recent meta-analyses demonstrated that the newer vola-
tile anesthetics sevoflurane and desflurane reduce postoper-
ative rise in cardiac TnI3 and result in decreased morbidity
and mortality.30 The present study demonstrates for the first
time that a preconditioning effect of sevoflurane in patients
having CABG depends on the preconditioning protocol.
We thank Yvonne Gru¨ber, technician, Department of Anesthesi-
ology, University Hospital of Du¨sseldorf, Du¨sseldorf, Germany,
for excellent technical support.
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DAPPENDIX E1
Anesthesia, Surgery, and Study Protocol
Acetylsalicylic acid therapy was discontinued 1 week prior
to surgery; all other preoperative medications were contin-
ued until the morning of the operation. All patients were pre-
medicated with 10 mg diazepam the night before and the
morning of the operation. Patient monitoring included con-
tinuous 5-lead electrocadiographic registration with ST-seg-
ment analysis (leads II and V5), pulse oximetry, invasive
radial artery blood pressure measurement, CVP, pulmonary
artery catheters with continuous mixed venous saturation
and cardiac output measurement (CCOmbo, Edwards Life-
science, Irvine, CA), capnography, rectal temperature, and
urine output.
After preoxygenation, anesthesia was induced by 20 mg
sufentanil and by starting a propofol target-controlled infu-
sion with a target plasma concentration of 2.5 mg/mL plasma.
Tracheal intubation was performed after muscle relaxation
with 0.1 mg/kg pancuronium bromide. Continuous infusion
of sufentanil (0.3 mg $ kg1 $ h1) and propofol target-con-
trolled infusion were used for maintenance of anesthesia.
Standard median sternotomy and pericardiotomy were
performed and the left internal thoracic artery was dissected
free. After systemic heparinization (300 IU/kg with addi-
tional doses to reach target-activated coagulation time>
400 s), arterial and venous cannulae for CPB were inserted
and secured in place. A tip manometer (MillarTip catheter,
Millar Instruments, Houston, TX) was inserted into the left
ventricle via the right superior pulmonary vein. The pressure
signal was digitally recorded on a computer system (Power-
Lab 4/30, ADinstruments, Spechbach, Germany). All hemo-
dynamic recordings were obtained during respiratory arrest
without positive end-expiratory pressure.
After registration of baseline values, a first sample of the
right atrium was obtained and immediately frozen in liquid ni-
trogen and stored at80C until further processing for immu-
noblotting. Sevoflurane preconditioning was than induced in
the SEVO-I and SEVO-II groups. Therefore, the ventilator
was set to a fresh gas flow of 12 L/min (FiO2 0.7), and the
vaporizer was set to reach an end-tidal concentration of 2The Journal of Thoracic and CardVol%. After 5 minutes, the vaporizer was set to 0 to wash
out sevoflurane. In the SEVO-II group, this maneuver was
repeated after 5 minutes. Ten minutes after the last sevoflur-
ane administration, or the corresponding time point in the
control group, we obtained a second sample of the right
atrium for immunoblotting. Then CPB was started and the
aorta was crossclamped. Cardiac arrest was achieved by
warm blood cardioplegia (34C). All distal anastomoses
were performed during aortic crossclamping with repeated
warm blood cardioplegia. The proximal anastomoses were
performed during reperfusion of the heart with partial clamp-
ing of the aorta. After completion of coronary artery grafting
and rewarming of the patient (rectal temperature 36C), CPB
was discontinued and heparin was antagonized by protamine
(in the ratio 1.5 mg per 100 IU heparin given). No patient re-
ceived aprotinin. The heart was paced in atrioventricular se-
quence mode with a frequency of 90 beats/min. According to
the study protocol, norepinephrine was used to keep MAP
above 70 mm Hg, and dobutamine was used to maintain
CI above 2.5 L $ min1 $ m2. All hemodynamics were mea-
sured 3 and 10 minutes after termination of CPB, and then
the MillarTip catheter was removed. An overview of the
time points of hemodynamic measurements and blood sam-
pling is given in Figure 1.
All operations were performed by the same surgeon, and
anesthesia was performed by 2 cardiothoracic anesthesiol-
ogists. Patients, surgeon, and perfusionists were blinded re-
garding the enrollment into the study groups. After
surgery, patients were transferred to the ICU and received
routine therapy, including fast weaning from the ventilator.
All decisions regarding medical care on the ICU and the
ward after the operation were made by physicians and
nurses blinded to the study protocol. Duration of postoper-
ative intubation was defined as time between end of oper-
ation and extubation in the ICU (in minutes). Length of
stay in ICU was defined as time between arrival at the
ICU and transfer to the ward (in hours). Length of stay
in hospital was defined as the time between day of opera-
tion and discharge from hospital to home or rehabilitation
facility (in days).iovascular Surgery c Volume 137, Number 6 1442.e1
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DTABLE E1. Global hemodynamics
Baseline
(T1)
SEVO-I
(T2)
WASH-I
(T3)
SEVO-II
(T4)
WASH-II
(T5)
Post-CPB
(T7)
End
(T9)
4 h
post-CPB
(T12)
8 h
post-CPB
(T13)
12 h
post-CPB
(T14)
24 h
post-CPB
(T15)
HR (1/min)
CON 69  17 76  20 97  10y 95  10y 96  11y 92  9y 93  8y 89  7y
SEVO-I 66  11 79  16 75  9 97  11y 93  8y 98  13y 99  18y 99  15y 94  12y
SEVO-II 64  18 65  13 66  15 66  15 69  13* 96  9y 89  9y 90  6y 90  8y 91  7y 90  11y
MAP (mm Hg)
CON 91  18 74  20 75  16 85  12 84  9 80  13 79  5 89  13
SEVO-I 95  17 69  14y 85  11 75  14y 82  14 86  16 90  9 77  12 84  11
SEVO-II 83  12 69  6 77  12 68  10y 81  10 85  13 90  10 77  7 80  9 82  13 90  11
PCWP (mm Hg)
CON 9  5 5  3 8  6 8  3 14  4 15  4 13  4 13  2
SEVO-I 9  4 7  4 7  4 7  3 9  4 13  4 13  2 13  2 12  2
SEVO-II 12  4 10  4 10  4 10  4 10  5* 13  6 12  5 13  3 13  4 13  2 13  3
CI (L $ min1 $ m2)
CON 2.4  0.4 2.6  1.1 2.8  1.1 2.7  0.6 2.7  0.4 2.8  0.5 2.9  0.6 3.3  0.5
SEVO-I 2.2  0.6 2.7  0.7 2.7  0.8 3.0  1.1 3.0  0.9 3.3  0.6 3.4  0.8y 3.3  1.0y 3.4  0.9y
SEVO-II 2.5  0.9 2.5  0.6 2.5  0.5 2.4  0.5 2.7  0.5 2.4  0.6 2.8  0.5 3.3  0.8 3.6  0.7* 3.3  0.5y 3.4  0.5y
HR, Heart rate; MAP, mean arterial pressure; PCWP, pulmonary artery wedge pressure; CI, cardiac index; CON, control group. For explanation of the time points and groups see
Figure 1; data are mean  standard deviation. *P< .05 versus control group; yP< .05 versus baseline.
TABLE E2. Laboratory testing
Baseline
(T1)
10 min
post-CPB (T7)
Arrival on
ICU (T10)
4 h post-CPB
(T12)
12 h post-CPB
(T14)
24 h post-CPB
(T15)
48 h post-CPB
(T16)
72 h post-CPB
(T17)
CK (U/L)
CON 57  25 n/a 576  252 605  244 595  241 598  328 629  572 456  373
SEVO-I 63  29 n/a 503  208 569  186 644  225 631  206 406  172 233  108
SEVO-II 69  36 n/a 576  282 609  339 595  269 701  486 442  265 213  101
CK-MB (U/L)
CON 10.8  2.3 n/a 38.1  19.1 26.8  11.1 21.6  8.1 15.7  12.9 14.3  13.8 10.8  9.0
SEVO-I 8.2  8.2 n/a 38.6  12.8 27.5  10.5 23.7  8.4 21.8  10.3 12.2  8.5 6.6  3.5
SEVO-II 5.2  2.9 n/a 28.6  16.1 22.4  15.2 18.9  10.2 20.2  17.4 8.8  8.1 4.9  5.3
BNP (pg/mL)
CON 17.2  9.9 32.6  14.1 38.8  14.1 52.6  25.4 90.0  34.4 141.3  60.1* 133.1  71.2* 146.1  104.0*
SEVO-I 14.3  10.4 33.6  27.8 35.5  22.4 45.7  31.9 72.0  51.8 158.5  77.6* 153.2  70.0* 149.9  80.8*
SEVO-II 34.8  30.5 37.7  29.4 48.7  34.4 59.7  36.7 141.3  84.2 233.5  155.3* 239.1  120.8* 247.2  123.5*
CK, Creatine kinase; CK-MB, MB isoform from CK; BNP, brain natriuretic peptide; ICU, intensive care unit; CPB, cardiopulmonary bypass; CON, control group. For explanation
of the time points and groups see Figure 1; data are mean  standard deviation. *P< .05 versus baseline.
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